Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Ann Surg Oncol. 2011 May;18(5):1293-9. doi: 10.1245/s10434-010-1437-x. Epub 2010 Nov 19.
Postoperative hypocalcemia is the most common complication after thyroidectomy; prevention and treatment remain areas of ongoing debate. The purpose of this study was to determine the incremental cost utility of routine versus selective calcium and vitamin D supplementation after total or completion thyroidectomy.
A cost-utility analysis using a Markov decision model was performed for a hypothetical cohort of adult patients after thyroidectomy. Routine or selective supplementation of oral calcium carbonate, vitamin D (calcitriol), and intravenous calcium gluconate, when required, was used. Selective supplementation was determined by serum intact parathyroid hormone levels. The incremental cost utility, measured in U.S. dollars per quality-adjusted life-year (QALY), was calculated.
In the base-case analysis, the cost of routine supplementation was $102 versus $164 for selective supplementation. Patients in the routine arm gained 0.002 QALYs compared to patients in the selective arm (0.95936 QALYs vs. 0.95725 QALYs). At the population level, this translates into a savings of $29,365/QALY (95% confidence interval, -$66,650 to -$1,772) for routine supplementation. Sensitivity analyses demonstrated that the model was most sensitive to the utility of the hypocalcemic state, postoperative rates of hypocalcemia, and cost of serum parathyroid hormone testing.
Routine oral calcium and calcitriol supplementation in patients after thyroidectomy seems to be less expensive and results in higher patient utility than selective supplementation. Surgeons who have very low rates of hypocalcemia in their patients may benefit less from routine supplementation.
甲状腺切除术后低钙血症是最常见的并发症;预防和治疗仍是持续争论的领域。本研究旨在确定甲状腺切除术后常规与选择性补钙和维生素 D 补充的增量成本效果。
采用马尔可夫决策模型对甲状腺切除术后的成人患者进行成本效果分析。使用常规或选择性补充碳酸钙、维生素 D(骨化三醇)和必要时的静脉葡萄糖酸钙。选择性补充取决于血清完整甲状旁腺激素水平。以每质量调整生命年(QALY)美元表示增量成本效果。
在基础分析中,常规补充的成本为 102 美元,而选择性补充的成本为 164 美元。常规组患者比选择性组患者获得 0.002 QALY(0.95936 QALY 比 0.95725 QALY)。在人群水平上,这意味着常规补充的成本效益为 29,365 美元/QALY(95%置信区间:-66,650 美元至-1,772 美元)。敏感性分析表明,该模型对低钙血症状态的效用、术后低钙血症的发生率和甲状旁腺激素检测的成本最为敏感。
甲状腺切除术后常规口服补钙和骨化三醇补充似乎比选择性补充更经济,且能提高患者的效用。术后低钙血症发生率非常低的外科医生可能从常规补充中获益较少。